First patient randomized in pivotal TRANSFORM study with setanaxib
/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been randomized in...
Source: prnewswire.com